The t(12;21)(p13;q22) is a cryptic abnormality observed in 25% of children with B-lineage acute lymphoblastic leukemia (ALL), associated with a favorable prognosis. To determine whether specific cytogenetic abnormalities accompany the t(12;21), we analyzed the cytogenetic profiles of blast cells from 169 ALL cases positive for the t(12;21), previously identified by molecular methods. Only 13.6% of samples had normal karyotypes. Structural changes were detected in 89.7% of abnormal karyotypes, and numerical abnormalities in 47%. Rearrangements of 12p were the most frequent structural aberration (57 out of 146 patients with chromosomal abnormalities). Nonspecific deletions of chromosomes 6 and 9 were also found. The most frequent numerical abnormalities was trisomy for chromosomes 21. Blast cells were pseudodiploid (45.6%), hyperdiploid with 47 to 51 chromosomes (24.3%), hypodiploid with 44 to 45 chromosomes (10%), near-triploid (0.6%), or near-tetraploid (5.9%). Our results show that the t(12;21) is not associated with hyperdiploidy of 52 to 68 chromosomes or with the prognostic t(1;19), t(4;11) or t(9;22). Only children with B-lineage ALL who lack these abnormalities detected by conventional cytogenetics will probably benefit from additional testing by molecular methods to detect the t(12;21).
Introduction
Nonrandom chromosomal translocations often result in the activation of genes located at the breakpoints and have been associated with many types of hematologic malignancies. 1 Of particular interest are chromosomal translocations in children with ALL, because several translocations are considered to be distinctive prognostic factors. 2 The use of cytogenetics to identify these chromosomal abnormalities has contributed to the overall strategy for the effective use of risk-specific cancer therapies, and karyotypic and genotypic analyses are used in determining proper treatment randomization. 3 A recent development has been the identification of a new recurrent translocation, t(12;21)(p13;q22), observed in patients with B-precursor ALL. 4 Undetectable by standard cytogenetics, this translocation is the most frequent genetic rearrangement in children with ALL; the t(12;21)(p13;q22) is present in approximately 25% of patients with the B-precursor subtype. [5] [6] [7] The result of the translocation at the molecular level is the fusion of the 5′ end of the ETV6 gene, a member of the ETS family, 8 to most of the AML1 gene. 9, 10 Interestingly, the ETV6-AML1 fusion gene is frequently associated with loss of the nontranslocated ETV6 allele, leading to the absence of functional ETV6 in leukemic cells. 9, 11 The association between t(12;21) and a favorable prognosis for children with B-precursor ALL has been shown to be statistically significant and independent, [5] [6] [7] patients expressing the ETV6-AML1 fusion product can be treated with less intensive therapy. However, it has been recently reported that the t(12;21) was found among a small number of patients who suffered relapse, reinforcing the need for further studies with longer follow-up periods to determine the true prognostic significance of the t(12;21) and to avoid premature changes in treatment strategies. 12, 13 Because the t(12;21) is virtually undetectable by conventional cytogenetics, we have analyzed the cytogenetic data of blast cells from 169 children with B-precursor ALL and with the t(12;21) previously identified by molecular methods to investigate the karyotypic profiles associated with the t(12;21).
Materials and methods

Patients
A total of 169 patients (96 male and 73 female) were included in this study. Ninety-eight children with newly diagnosed Bprecursor ALL were referred to St Jude Children's Research Hospital (SJCRH) and enrolled in four consecutive front-line clinical trials (Total Therapy Studies X to XIII). 14, 15 The other 71 children were treated at nine pediatric centers in France as part of therapeutic trial 58881 for the European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group (EORTC). 16 The diagnosis of ALL was based on the morphologic criteria of the French-AmericanBritish Cooperative Group and on negative myeloperoxidase and esterase stains. The diagnosis of B-precursor ALL was based on the expression of B cell-associated antigens (CD19, CD22, CD10) and the absence of membrane immunoglobulin. Informed consent was obtained from all patients or their guardians, and the investigations were approved by the institutions' clinical trials review committees.
Cytogenetic evaluation
Bone marrow samples were prepared by a direct method or from unstimulated cultures that were grown overnight or for 24 or 48 h. 17 Chromosomes were identified by using trypsinWright's banding techniques, RHG banding techniques, or both and were classified according to the International System for Human Cytogenetic Nomenclature.
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ETV6 rearrangements and ETV6-AML1 fusions
At SJCRH, the t(12;21) was initially identified by Southern blotting and in most cases was subsequently confirmed by RT-PCR. 6, 19 For 45 patients enrolled in the EORTC trial, the expression of fusion products ETV6-AML1 or AML1-ETV6 was evaluated by RT-PCR using described amplification primers and probes.
9,10 ETV6 rearrangements were detected in metaphase/interphase cells from the other 26 patients by fluorescence in situ hybridization (FISH) using a set of cosmid probes specific for the 5′ and 3′ ends of the ETV6 gene as previously described.
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Results
Normal karyotypes are rarely associated with leukemic cells bearing a t (12;21) Of the 169 children with B-precursor ALL and a t(12;21) detected by molecular methods, only 23 (approximately 14%) had a normal karyotype as detected by conventional cytogenetic methods.
Abnormal cell lines/complexity
Single leukemic cell lines were observed in bone marrow of 120 (82.2%) of the 146 patients with chromosomal abnormalities. Multiple lines were observed in samples from the other 26 patients: clonal evolution occurred in 23 cases, and independent transforming events resulted in unrelated cell lines in three cases. Furthermore, a single chromosomal abnormality was observed in cell lines from 58 patients (39.7%), whereas more than one chromosomal abnormality was observed in lines derived from 88 patients (60.3%).
Structural abnormalities
Structural changes were detected in samples from 131 of the 146 patients (89.7%) with chromosomal abnormalities. As shown in Figure 1 , breakpoints involved all chromosome arms except for Yp, Yq, 10p, 13p, 14p and 20q. The most frequently observed chromosome arms involved in breakpoints were 12p (n = 57 cases with 65 breakpoints), 6q (n = 23), 9p (n = 13), 6p (n = 10), 15q (n = 10), 3p (n = 9), 9q (n = 9), 11q (n = 9), 13q (n = 9), 5q (n = 8) and 22q (n = 8).
Aberrations affecting 12p are the most frequent abnormalities associated with the t(12;21):
A total of 65 structural changes in 12p were identified in 57 patients (39%) who had abnormal karyotypes. Both 12p homologs were abnormal in samples from six patients. In two independent cell lines derived from single samples, one homolog of 12p was rearranged in each line. Of the 65 abnormalities of 12p that were detected by conventional cytogenetics, 47 (72%) were loss of DNA material, 17 (26%) were balanced translocations, and one (2%) was an inversion, inv(12)(p12q24). The loss of 12p resulted from deletions (n = 23), dicentric [dic(9;12) (n = 6) and dic(12;15) (n = 1)], and unbalanced translocations with exchanged material of unknown (n = 11) or known (n = 6) origin. The 12p known chromosome partners included 13q12 (n = 2), 4q13, 5q12, 13q? and 22q11.2. The balanced translocations included a recurrent t(12;13)(p13;q13-14) (n = 2) and translocations involving partners at chromosomal bands 1p21, 1p22, 1q22, 3q11, 4q21, 5q12, 5q22, 6p11, 8p21, 8q11, 9q13, 15q11, 17p13, 17q12, and 18q11.
Partial chromosome losses are frequently associated with the t(12;21):
Additional structural rearrangements affecting chromosome arms besides 12p were also identified. As results of these changes, partial chromosome losses were more frequent than partial chromosome gains (Figure 2a and b) . Deletion of 6q was detected in cells from 19 patients, accounting for 13% of abnormal karyotypes and 83% of the 6q abnormalities (n = 23). Loss of 9p resulted from deletions (n = 6), dic(9;12) (n = 6) and dic(9;18) (n = 1), accounting for approximately 9% of abnormal karyotypes. The long arm of chromosome 11 was affected by deletions from q12 to q23 (n = 6) and by random translocations (n = 3). Nine patients had abnormalities of 13q. Besides involvement in balanced and unbalanced t(12;13) (n = 5) that frequently resulted in partial monosomy 13 (n = 3), 13q was also involved in two deletions and in two random translocations. Involvement of 15q15 (n = 4) accounted for more than one-third of the structural abnormalities of chromosome 15 (n = 10). Loss of 15q material occurred in cells from five patients by deletions (n = 3) or unbalanced translocations with unidentified material (n = 2). An isochromosome 21q was observed in two cases. Rearrangements of chromosome 22 (n = 8), including one deletion and four random balanced translocations were observed, with preferred involvement of 22q11.2 (n = 5). Finally, material of unknown origin was frequently observed (31%, 46/146 cases) in the form of marker chromosomes or additional material.
Cells from all patients were negative for the t(1;19), t(4;11), and t(9;22):
This was shown by conventional cytogenetics, and by RT-PCR analysis for the majority of them (data not shown). These translocations are known as indicators of a poor prognosis.
Numerical abnormalities
Numerical abnormalities were detected in cells from 47% of the patients (69/146) with chromosomal abnormalities. Seventy-eight percent of the patients with numerical abnormalities also had structural abnormalities. Overall, the most frequent numerical abnormalities were gain of chromosomes. The trisomies observed were for chromosomes 21 (n = 25), 10 (n = 8), 6 (n = 7), X (n = 4), 2 (n = 2), 3 (n = 2), 16 (n = 2), 19 (n = 2), 4 (n = 1), 11 (n = 1), 12 (n = 1), 17 (n = 1), 18 (n = 1), 20 (n = 1) and 22 (n = 1). Except for monosomy of chromosome X (n = 11), the absence of entire chromosomes was rare. Monosomy of chromosome 9 was seen in three cases; monosomy of chromosomes 3, 13, 15, 22 and Y was seen in two cases each; monosomy of chromosomes 4, 8, 12, 14, and 19 was seen in one case each. The distributions of the frequencies of chromosome losses and gains are given in Figure  2a 
Modal number
A diploid modal number was found in samples from 23 patients (13.6%). Pseudodiploidy was found in samples from 77 patients (45.6%). Samples from 16 of the 17 patients with hypodiploidy had 45 chromosomes; the other had 44 chromosomes. Most patients with hyperdiploidy had 47 (n = 34) or 48 chromosomes (n = 5); cells from three patients either had 49 chromosomes, had 51 chromosomes, or were near-triploid. In addition, there were leukemic lines from 10 patients that were near-tetraploid. Therefore, hypodiploidy accounted for 10% of the study population, hyperdiploidy of 47 to 51 chromosomes accounted for 24.3%, near-triploidy accounted for 0.6%, and near-tetraploidy accounted for 5.9%.
Discussion
We have performed a comprehensive karyotypic analysis of blast cells from 169 children with B-precursor ALL and a t(12;21) previously detected by molecular methods. This recurrent translocation, which is found in approximately 25% of children with ALL, 5-7 is undetectable by conventional cytogenetics. 4 Therefore, it was of interest to determine whether any specific cytogenetic profiles were associated with the t(12;21). In this series, only 13.6% (n = 23) of the patients had a diploid karyotype. Thus, most children with the t(12;21) had abnormal karyotypes. Moreover, 88 of the 146 patients with chromosomal abnormalities (60.3%) had complex karyotypes with two or more chromosome changes in addition to the cryptic t (12;21) .
Structural abnormalities were detected in cells from approximately 90% (n = 131/146) of the patients with the t(12;21) and an abnormal karyotype; rearrangements involving 12p were the most frequent (39%). Initial reports of the cloning of the t(12;21)(p13;q22), which fuses the ETV6 gene on 12p13 to the AML1 gene on 21q22, showed that the nontranslocated allele of ETV6 was deleted in each of the four original cases. 9, 10 This finding was confirmed in larger series by loss of heterozygosity (LOH) studies and FISH analyses using cosmid probes specific for the ETV6 gene. 11, 21, 22 Therefore, microscopic and submicroscopic deletions of the nontranslocated allele of ETV6 seem to be associated with the t(12;21) in children with ALL. These deletions are considered to be a secondary event. 11 On the basis of our cytogenetic data, microscopic deletions of the 12p region accounted for only 32% (47/146) of the cases. In this study, whether the translocations involving 12p13 were balanced three-way t(12;21) translocations, or contributed to the loss of the nontranslocated allele of ETV6 remains to be determined. Overall, 17 balanced translocations involving 12p were observed, and an additional 21 distinct breakpoints were found as partners in 12p translocations, either balanced or unbalanced. Another chromosomal region affected mainly through a dic(9;12)(p12;p12) was the 9p11-13, probably contributing to the deletion process of the non-translocated ETV6 allele.
Two-thirds of the cases had additional structural rearrangements affecting chromosome arms other than 12p. As a result of these changes, partial chromosomal losses, including recurrent del(6q), del(9p), del(11q), del(13q) and del(15q), were frequent. Notably, most of these cases also contained marker chromosomes with DNA of unknown origin that could have been segments originally belonging to the deleted regions. Therefore, additional molecular techniques are needed to assess the partial chromosome losses frequently found in t(12;21)-positive cases, as microdeletions often result in tumor suppressor gene inactivation that plays an important role in leukemogenesis. Indeed, the complex karyotypes observed in this series in addition to the t(12;21) suggest a multistep model of oncogenesis, similar to that described for instance in colon carcinoma. 23 Recent studies on ETV6 fusions and/or acquisition of CDKN2 deletions have already pointed to the exist- ence of multistep carcinogenesis in B-lineage ALL. 24, 25 Consistent with this hypothesis is the description of the same clonotypic ETV6-AML1 genomic fusion sequence in pairs of identical twins with cALL, indicative of a fetal in utero hematopoiesis origin of the fusion gene seen at onset of the disease; 26 scrutiny of Guthrie blood spots of twin and non-twin children with cALL using a very sensitive PCR confirms the prenatal origin of some pediatric cALL between the ages of 2 and 14 years, and points to ETV6-AML1 gene fusion as a very early and probable initiating event. 27 The modest concordance rate for cALL in identical twins let these authors suggest that post-natal exposures may be required for the development of ALL after pre-natal initiation. 27 An important secondary event is the loss of the non-translocated ETV6 allele. The secondary chromosomal abnormalities described in our series may be reflecting additional molecular events.
From this series five cases had balanced or unbalanced t(12;13). Interestingly, the ETV6 gene has been shown to be fused to the homeobox gene CDX2 in a patient with acute myeloid leukemia and a t(12;13)(p13;q12), 28 and a preliminary study by Coignet et al 29 suggests that myeloid-and lymphoid-specific breakpoint cluster regions are present within chromosome 13q14 in patients with acute leukemia and with a t(12;13)(p12;q12-14).
None of the recurrent translocations commonly identified in children with ALL, ie the t(1;19), t(4;11) and t(9;22), were seen in this study using conventional cytogenetics and RT-PCR analysis. All three of these translocations are indicators of a poor prognosis. 2, 3 The absence of t(4;11) and t(9;22) could explain, at least in part, the good prognosis of children with ETV6-AML1 rearrangement.
Of the 69 patients with numerical changes, 25 had trisomy of chromosome 21, the most frequent numerical abnormality. Interestingly, chromosome 21 In our group of t(12;21)-positive patients with ALL, the modal chromosome numbers were different from those of children with ALL in general. Overall, in this series the blast cells from approximately 93% of the patients had modal chromosome numbers ranging from 44 to 49 (n = 157); 11 had modal chromosome numbers in the near-triploid (n = 1) or near-tetraploid (n = 10) range. Although cells from one patient had a modal chromosome number of 51, none of the other patients in our study displayed near-haploidy or hyperdiploidy of 52 to 68 chromosomes. In contrast, 25% of children with ALL generally have blast cells that are hyperdiploid with 52 to 68 chromosomes. 2, 3 Pseudodiploidy was observed in approximately 60% of the t(12;21)-positive cases; generally, pseudodiploidy is observed in 45% to 50% of cases of ALL. 2, 3 In conclusion, the t(12;21) was not associated with recurrent translocations of known prognostic values [t(1;19), t(4;11) or t(9;22)] or hyperdiploidy of 52 to 68 chromosomes. The t(12;21) is mostly present with nonrecurrent abnormal complex karyotypes characterized by modal chromosomal numbers ranging from 45 to 51, 12p rearrangements, nonspecific deletions of chromosomes 6 and 9, and trisomy 21. Although this study was performed retrospectively and may be biased by the availability of samples, our study delineates the cytogenetic profile of blast cells from children with ALL and a t(12;21). These findings may be beneficial to other investigators for the selection of cases for further analysis by RT-PCR or FISH to identify this cryptic t(12;21).
